SCHEMBL22206362

SCHEMBL22206362

CS(=O)(=O)c1ccc(-c2ccc3nn(C/C(=C/F)CN)c(=O)n3c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SCN5A Q14524 5/20 0.38
▸ FLT3 P36888 2/20 0.37
▸ SCN1A P35498 1/20 0.36
▸ SCN2A Q99250 1/20 0.36
▸ LMNA P02545 1/20 0.35
▸ KCNH2 Q12809 2/20 0.35
▸ GPR139 Q6DWJ6 3/20 0.34
▸ PTGS2 P35354 2/20 0.34
▸ PTGS1 P23219 1/20 0.34
▸ AOC3 Q16853 2/20 0.33
▸ CA12 O43570 2/20 0.33
▸ CA9 Q16790 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL23736451 0.93 SCN5A (0.38) SCN5AFLT3SCN1ASCN2ALMNA
SCHEMBL22099137 0.83 POLB (0.42) LMNAALDH1A1
SCHEMBL22206311 0.82 SMN1; SMN2 (0.38) SCN5ASCN1ASCN2AGPR139AOC3
SCHEMBL22099134 0.82 SCN5A (0.40) SCN5ASCN1ASCN2AGPR139AOC3
SCHEMBL22206360 0.81 SCN5A (0.36) SCN5ASCN1ASCN2AGPR139
Hydrochloric Acid SCHEMBL22206373 0.81 SCN5A (0.40) SCN5ASCN1ASCN2AGPR139AOC3
SCHEMBL22099133 0.80 SCN5A (0.38) SCN5ASCN1ASCN2AGPR139AOC3
Hydrochloric Acid SCHEMBL22206410 0.79 SCN5A (0.38) SCN5ASCN1ASCN2AGPR139AOC3
SCHEMBL22206343 0.79 AOC3 (0.38) SCN5AAOC3
SCHEMBL22206303 0.78 GPR139 (0.47) GPR139

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820769-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2023-11-21 — — US claimed
US-20220024918-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2022-01-27 — — US claimed
US-11091479-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2021-08-17 — — US claimed
US-20200223844-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2020-07-16 — — US claimed
US-11820769-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2023-11-21 — — US disclosed
US-11820769-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2023-11-21 — — US disclosed
US-11820769-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2023-11-21 — — US disclosed
US-20220024918-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2022-01-27 — — US disclosed
US-20220024918-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2022-01-27 — — US disclosed
US-11091479-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2021-08-17 — — US disclosed
US-11091479-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same YUHAN CORPORATION (KR) 2021-08-17 — — US disclosed
US-20200223844-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2020-07-16 — — US disclosed
US-20200223844-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2020-07-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11091479-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same VAPB, HDLBP, VAPA SCN5A 2529/4885FLT3 3491/4885SCN1A 1343/4885
US-11820769-B2 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same VAPB, HDLBP, VAPA SCN5A 2529/4885FLT3 3491/4885SCN1A 1343/4885
US-20200223844-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME VAPB, HDLBP, VAPA SCN5A 2529/4885FLT3 3491/4885SCN1A 1343/4885
US-20220024918-A1 TRIAZOLOPYRIDIN-3-ONES OR THEIR SALTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME VAPB, HDLBP, VAPA SCN5A 2529/4885FLT3 3491/4885SCN1A 1343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback